SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Glimelius Bengt) "

Sökning: WFRF:(Glimelius Bengt)

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
31.
  • Andréasson, Håkan, et al. (författare)
  • Outcome differences between debulking surgery and cytoreductive surgery in patients with pseudomyxoma peritonei
  • 2012
  • Ingår i: European Journal of Surgical Oncology. - 0748-7983 .- 1532-2157. ; 38:10, s. 962-968
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND:The aim of this study was to compare debulking surgery and cytoreductive surgery (CRS) in patients with Pseudomyxoma peritonei (PMP) regarding efficacy and safety.PATIENTS AND METHODS:Data were extracted from medical records and treatment outcomes were analyzed for all 152 patients with PMP who were scheduled for debulking surgery and intraperitoneal chemotherapy (IPC) or CRS and IPC at Uppsala University Hospital, Uppsala, Sweden, between September 1993 and December 2008.RESULTS:One hundred and ten patients (73%) were treated with CRS and IPC and 40 (27%) with debulking surgery and IPC. In two patients (1%), surgery was defined as open and close. Patients with CRS and IPC had a 74% 5-year overall survival (OS) rate compared with 40% for those treated with debulking surgery (P < 0.001). Patients with no residual macroscopic tumour (R1 resection) had a better 5-year OS rate of 94% compared with 28% for patients with macroscopic residual tumour (R2) (P < 0.001). Grades II-IV adverse events were seen in 29% of debulked patients and in 47% of CRS/IPC patients (P = 0.053).CONCLUSIONS:CRS and IPC seems more efficient than debulking surgery and IPC but with numerically higher morbidity. Therefore, if surgically possible, CRS should be the treatment of choice for PMP patients. However, debulking surgery may still be of benefit to selected patients for palliative purposes.
  •  
32.
  •  
33.
  • Arving, Cecilia, et al. (författare)
  • Cost-utility analysis of individual psychosocial support interventions for breast cancer patients in a randomized controlled study
  • 2014
  • Ingår i: Psycho-Oncology. - 1057-9249 .- 1099-1611. ; 23:3, s. 251-258
  • Tidskriftsartikel (refereegranskat)abstract
    • Background The Distress Thermometer (DT) has been used in psycho-oncology research across the globe and has been recommended as a clinical tool to be used routinely in cancer settings to detect clinically significant distress. We sought to characterize the translation and validation of the DT in cancer patients in different countries and cultures and summarize how the translated versions function to detect clinically significant distress. Methods An electronic mail survey was sent to the members of the International Psychosocial Oncology Society Federation of Psycho-Oncology Societies and electronic searches of English language databases were conducted to identify translations of the DT and studies designed to validate these translations. Results Our efforts yielded a total of 21 non-English translations of the DT; 18 of these were validated in studies designed for that purpose. A variety of instruments were used in receiver operating characteristic curve analysis to derive an optimal cut-off score indicative of clinically significant distress. Cut-off scores varied by language, country, and clinical setting and to sample characteristics. In the majority of studies, a score of 4 maximized sensitivity and specificity relative to an established criterion. Conclusions These findings provide a broad, international perspective on the current state of psychosocial screening using the DT. Findings also demonstrate widespread awareness of the need for psychological and social support of persons diagnosed with and treated for cancer.
  •  
34.
  • Arving, Cecilia, et al. (författare)
  • Four weeks of daily assessments of anxiety, depression and activity compared to a point assessment with the Hospital Anxiety and Depression Scale
  • 2008
  • Ingår i: Quality of Life Research. - 0962-9343 .- 1573-2649. ; 17:1, s. 95-104
  • Tidskriftsartikel (refereegranskat)abstract
    • Objectives To explore to what extent the daily reporting of anxiety, depression and activity in a diary mirrors scores on point assessments with the Hospital Anxiety and Depression scale ( HADS). Methods In a randomized intervention study consecutive breast cancer patients ( n = 179) about to start adjuvant therapy were included. The HADS questionnaires were sent to patients 3 and 12 months after inclusion. Daily reporting of anxiety, depression and activity on Visual Analogue Scales ( VAS) were completed during 4 weeks surrounding the HADS assessments. Results The results showed moderate correlations ( r = -0.36 to -0.67, P < 0.01) at both assessments. The daily reports were consistent over 4 weeks and did not differ between assessments. Mean scores on the HAD-Anxiety were 4.00 at the 3 months and 5.07 at the 12 months assessment. For the HAD-Depression the mean scores at the same assessment points were 3.61 and 3.23, respectively. The daily reports put more strain on the respondents and produced a larger attrition rate than the HADS. Conclusion A point assessment with the HADS captures the situation of breast cancer patients' equivalent to 4 weeks assessment in a diary, but is easier to complete and is therefore preferable to the diary.
  •  
35.
  • Arving, Cecilia, et al. (författare)
  • Individual psychosocial support for breast cancer patients : A randomized study of nurse vs. psychologist interventions and standard care
  • 2007
  • Ingår i: Cancer Nursing. - 0162-220X .- 1538-9804. ; 30:3, s. E10-E19
  • Tidskriftsartikel (refereegranskat)abstract
    • In a prospective, randomized study, an individual psychosocial support intervention performed by specially trained oncology nurses, or psychologists, were compared with standard care. Consecutive primary breast cancer patients about to start adjuvant therapy (n = 179) were included. Data were supplied by the questionnaires European Organisation for Research and Treatment of Cancer Quality of Life Study Group Core Quality of life questionnaire with 30 questions (EORTC QLQ-C30) and Breast Cancer Module with 23 questions (BR23), the Hospital Anxiety and Depression Scale, Spielberger's State-Trait Anxiety Inventory, and the Impact of Event Scale before randomization and 1, 3, and 6 months later. Patient files provided data on utilization of psychosocial support offered in routine care. Global quality of life/health status, nausea and vomiting, and systemic therapy side effects were the subscales showing significant Group by Time interactions, favoring the interventions. Intervention groups improved statistically significantly more than the standard care group regarding insomnia, dyspnea, and financial difficulties. Nurse patients experienced less intrusion compared with the standard care group. All groups showed statistically and clinically significant improvements with time on several subscales. The intervention groups, however, improved to a greater extent. Fewer patients in the intervention groups used psychosocial hospital support compared with the standard care group. In conclusion, psychosocial support by specially trained nurses using techniques derived from cognitive behavioral therapy is beneficial for breast cancer patients and may be a realistic alternative in routine cancer care.
  •  
36.
  • Arving, Cecilia, et al. (författare)
  • Satisfaction, utilisation and perceived benefit of individual psychosocial support for breast cancer patients : A randomised study of nurse versus psychologist interventions
  • 2006
  • Ingår i: Patient Education and Counseling. - 0738-3991 .- 1873-5134. ; 62:2, s. 235-243
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective: In a prospective, randomised study, individual psychosocial support performed by: (1) specially trained oncology nurses (INS) or (2) psychologists (IPS) were compared with respect to utilisation, satisfaction and perceived benefit.Methods: Between December 1997 and December 1999, consecutive breast cancer patients (n = 120) were included at start of adjuvant therapy (chemo-, endocrine and/or loco-regional radiotherapy). Data were collected by an extended version of the 'IPS-patient satisfaction questionnaire' within I week after termination of the support intervention. Questionnaires were also mailed to all patients 6, 12 and 18-24 months after inclusion. Levels of distress were collected with the Hospital Anxiety and Depression Scale (HADS) and Impact of Event Scale (IES) questionnaires.Results: The patients were highly satisfied with the individual psychosocial support intervention they received, irrespective of which profession provided the support. However, the patients in the INS group reported higher levels of benefit regarding disease-related problems, regardless if the patients at baseline reported low or high levels of distress.Conclusions: Patients were highly satisfied with an individual psychosocial support intervention. In areas dealing with somatic aspects, the group intervened by nurses were more satisfied than the one by psychologists.Practice implications: Individual psychosocial support by specially trained nurses is a realistic alternative in routine cancer care.
  •  
37.
  • Ask, Anders, et al. (författare)
  • The potential of proton beam radiation therapy in head and neck cancer.
  • 2005
  • Ingår i: Acta oncologica (Stockholm, Sweden). - 0284-186X. ; 44:8, s. 876-80
  • Tidskriftsartikel (refereegranskat)abstract
    • A group of Swedish oncologists and hospital physicists have estimated the number of patients in Sweden suitable for proton beam therapy. The estimations have been based on current statistics of tumour incidence, number of patients potentially eligible for radiation treatment, scientific support from clinical trials and model dose planning studies and knowledge of the dose-response relations of different tumours and normal tissues. In head and neck cancer, including thyroid cancer, it is assessed that at least 300 patients annually will gain sufficiently from proton beam therapy, both to improve tumour control and to decrease toxicity to compensate for the increased treatment costs using protons.
  •  
38.
  • Babaei, Masoud, et al. (författare)
  • Administration of adjuvant chemotherapy for stage II-III colon cancer patients : An European population-based study
  • 2018
  • Ingår i: International Journal of Cancer. - WILEY. - 0020-7136 .- 1097-0215. ; 142:7, s. 1480-1489
  • Tidskriftsartikel (refereegranskat)abstract
    • The advantage of adjuvant chemotherapy (ACT) for treating Stage III colon cancer patients is well established and widely accepted. However, many patients with Stage III colon cancer do not receive ACT. Moreover, there are controversies around the effectiveness of ACT for Stage II patients. We investigated the administration of ACT and its association with overall survival in resected Stage II (overall and stratified by low-/high-risk) and Stage III colon cancer patients in three European countries including The Netherlands (2009-2014), Belgium (2009-2013) and Sweden (2009-2014). Hazard ratios (HR) for death were obtained by Cox regression models adjusted for potential confounders. A total of 60244 resected colon cancer patients with pathological Stages II and III were analyzed. A small proportion (range 9-24%) of Stage II and over half (range 55-68%) of Stage III patients received ACT. Administration of ACT in Stages II and III tumors decreased with higher age of patients. Administration of ACT was significantly associated with higher overall survival in high-risk Stage II patients (in The Netherlands (HR; 95%CI = 0.82 (0.67-0.99), Belgium (0.73; 0.59-0.90) and Sweden (0.58; 0.44-0.75)), and in Stage III patients (in The Netherlands (0.47; 0.43-0.50), Belgium (0.46; 0.41-0.50) and Sweden (0.48; 0.43-0.54)). In Stage III, results were consistent across subgroups including elderly patients. Our results show an association of ACT with higher survival among Stage III and high-risk Stage II colon cancer patients. Further investigations are needed on the selection criteria of Stages II and III colon cancer patients for ACT.
  •  
39.
  • Babaei, Masoud, et al. (författare)
  • Neoadjuvant Therapy in Rectal Cancer Patients With Clinical Stage II to III Across European Countries : Variations and Outcomes
  • 2018
  • Ingår i: Clinical colorectal cancer. - 1533-0028. ; 17:1, s. E129-E142
  • Tidskriftsartikel (refereegranskat)abstract
    • This study is the largest observational study on neoadjuvant therapy in patients with stage II & III rectal cancer by including high-quality data from large population-based and clinical cancer registries. We observed large variations in administration of neoadjuvant chemo(radio) therapy across European countries. Our results support major survival advantages of patients treated with neoadjuvant radiotherapy. Background: Neoadjuvant therapy improves survival of patients with clinical stage II and III rectal cancer in clinical trials. In this study, we investigated the administration of neoadjuvant radiotherapy (neo-RT) and neoadjuvant chemoradiotherapy (neo-CRT) and its association with survival in resected patients in 2 European countries (The Netherlands and Sweden) and at 3 specialist centers. Materials and Methods: Administration of neoadjuvant treatment (all registries) and overall survival after surgery in The Netherlands and Sweden were assessed. Hazard ratios (HRs) were obtained using Cox regression adjusted for potential confounders. Results: A total of 16,095 rectal cancer patients with clinical stage II and III were eligible for analyses. Large variations in administration of neo-RT and neo-CRT were observed. Elderly patients less often received neo-RT and neo-CRT. Patients with stage III disease received neo-CRT more frequently than neo-RT. Administration of neo-RT versus surgery without neoadjuvant treatment was significantly associated with improved survival in The Netherlands (HR, 0.62; 95% confidence interval [CI], 0.53-0.73) as well as in Sweden (HR, 0.79; 95% CI, 0.69-0.90). Administration of neo-CRT was associated with enhanced survival in The Netherlands (HR, 0.62; 95% CI, 0.50-0.78) but not in Sweden (HR, 0.97; 95% CI, 0.80-1.18). The mortality of patients treated with neo-CRT compared with neo-RT showed inconsistent results in population-based centers. Conclusions: Our results support an association of neo-RT with enhanced survival among stage II and III rectal cancer patients. Comparing neo-CRT with neo-RT, larger variations and inconsistent results with respect to survival were observed across centers.
  •  
40.
  • Baecklund, Fredrik, et al. (författare)
  • A comprehensive evaluation of the role of genetic variation in follicular lymphoma survival
  • 2014
  • Ingår i: BMC Medical Genetics. - 1471-2350 .- 1471-2350. ; 15, s. 113
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Survival in follicular lymphoma (FL) is highly variable, even within prognostic groups defined by tumor grade and the Follicular Lymphoma International Prognostic Index. Studies suggest that germline single nucleotide polymorphisms (SNPs) may hold prognostic information but further investigation is needed. Methods: We explored the association between SNPs and FL outcome using two approaches: 1) Two independent genome-wide association studies (GWAS) of similar to 300.000 SNPs followed by a meta-analysis encompassing 586 FL patients diagnosed in Denmark/Sweden 1999-2002 and in the United States 2001-2006; and 2) Investigation of 22 candidate-gene variants previously associated with FL outcome in the Danish/Swedish cohort (N = 373). We estimated time to lymphoma-specific death (approach 1 and 2) and lymphoma progression (approach 2) with hazard ratios (HR) and 95% confidence intervals (CI) in a multivariable Cox regression model. Results: In the GWAS meta-analysis, using a random effects model, no variants were associated with lymphoma-specific death at a genome-wide significant level (p < 5.0x10(-8)). The strongest association was observed for tightly linked SNPs on 17q24 near the ABCA10 and ABCA6 genes (rs10491178 HRrandom = 3.17, 95% CI 2.09-4.79, prandom = 5.24x10(-8)). The ABCA10 and ABCA6 genes belong to a family of genes encoding for ABC transporter proteins, implicated in multidrug resistance. In line with a previous study, rs2466571 in CD46 (HR = 0.73, 95% CI 0.58-0.91, p = 0.006) showed nominal association with lymphoma progression, as did two highly linked SNPs in IL8 (rs4073 HR = 0.78, 95% CI 0.62-0.97, p = 0.02; rs2227307 HR = 0.75, 95% CI 0.60-0.94, p = 0.01) previously associated with overall survival. Conclusions: The results suggest a possible role for multidrug resistance in FL survival and add to the evidence that genetic variation in CD46 and IL8 may have prognostic implications in FL. Our findings need further confirmation in other independent populations or in a larger multicenter GWAS.
Skapa referenser, mejla, bekava och länka
Åtkomst
fritt online (45)
Typ av publikation
tidskriftsartikel (476)
forskningsöversikt (15)
annan publikation (9)
bokkapitel (4)
recension (2)
samlingsverk (redaktörskap) (1)
visa fler...
konferensbidrag (1)
doktorsavhandling (1)
visa färre...
Typ av innehåll
refereegranskat (404)
övrigt vetenskapligt (103)
populärvet., debatt m.m. (2)
Författare/redaktör
Glimelius, Bengt, (502)
Adami, Hans Olov (49)
Melbye, Mads (47)
Påhlman, Lars, (45)
Hjalgrim, Henrik (41)
Pahlman, L, (31)
visa fler...
Nygren, Peter, (27)
Berglund, Åke, (26)
Sorbye, Halfdan, (25)
Sjödén, Per-Olow (21)
Berglund, A. (19)
Nordin, Karin, (19)
Smedby, Karin E. (19)
Johansson, Birgitta (16)
Conde, Lucia (16)
Skibola, Christine F ... (16)
Sundström, Christer, (15)
Sundstrom, C, (15)
Bracci, Paige M (15)
de Sanjose, Silvia, (15)
Maynadie, Marc, (15)
Benavente, Yolanda, (14)
Cozen, Wendy, (14)
Nieters, Alexandra, (14)
Vajdic, Claire M., (14)
Enblad, Gunilla, (13)
Van Cutsem, Eric (13)
Ponten, Fredrik (13)
Boffetta, Paolo (13)
Brennan, Paul (13)
Spinelli, John J., (13)
Cerhan, James R., (13)
Lan, Qing, (13)
Morton, Lindsay M., (13)
Purdue, Mark P., (13)
Slager, Susan L., (13)
Berndt, Sonja I (12)
Chanock, Stephen J (12)
Foretova, Lenka (12)
Becker, Nikolaus (12)
McKay, James (12)
Bystrom, P (12)
Pahlman, Lars, (12)
Clavel, Jacqueline, (12)
Monnereau, Alain, (12)
Rothman, Nathaniel, (12)
Severson, Richard K. ... (12)
Staines, Anthony, (12)
Zhang, Yawei, (12)
Zheng, Tongzhang, (12)
visa färre...
Lärosäte
Uppsala universitet (497)
Karolinska Institutet (250)
Lunds universitet (46)
Umeå universitet (33)
Göteborgs universitet (16)
Linköpings universitet (16)
visa fler...
Kungliga Tekniska Högskolan (6)
Örebro universitet (3)
Högskolan i Jönköping (1)
Stockholms universitet (1)
visa färre...
Språk
Engelska (487)
Svenska (6)
Odefinierat språk (5)
Danska (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (454)
Naturvetenskap (9)
Teknik (4)
Samhällsvetenskap (1)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy